-
FDA accelerates approval of innovative FGFR inhibitors Liantuo Biotech owns development rights in China
Time of Update: 2021-06-11
On May 28, 2021, BridgeBio Pharma through its subsidiary company QED Therapeutics and Helsinn Group announced that the US FDA has accelerated the approval of Truseltiq (infigratinib) for the treatment of locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or rearrangement (CCA) Treated patients.
-
Department of Finance: further restrictions on imports of medical devices
Time of Update: 2021-06-11
Procurement of imported equipment will be supervised throughout the process In addition to Hangzhou, in February this year, the Guangdong Provincial Department of Finance also issued the "Notice on Optimizing Administration of Provincial Government Procurement of Imported Products", which also requires strict review of government procurement of imported products .
-
BeiGene, Genxi Biological, Kangfang Biological, Chia Tai Tianqing, etc. announce ASCO clinical data
Time of Update: 2021-06-11
The study selected for ASCO this time is a multi-center phase 2 registered clinical trial data of taletrectinib for ROS1 fusion non-small cell lung cancer patients.
At this conference, Kangfang Bio will announce the Phase 2 clinical study of AK104 combined with tyrosine kinase inhibitor lenvatinib in the first-line treatment of unresectable liver cancer.
-
The CEO and CFO of Hanhui Pharmaceutical have changed
Time of Update: 2021-06-11
Since June 1, Li Yan stepped down as the CEO of Hanhui Pharmaceuticals and was replaced by Hu Zhiqiang, reporting to the company’s chairman Liu Qi. According to Dami’s understanding, today Hanhui Pharmaceutical also announced a number of personnel changes in important positions, including Yu Tieming’s resignation as the company’s chief financial officer, Li Hao’s succession, and the appointment of He Dong as the vice president of the National Commercial and Diversified Business Department.
-
ASCO 2021 highlight moment!
Time of Update: 2021-06-11
2 In terms of "Shuang Ai combination" combined with other treatments, the team of Professor Xing Wenge from Tianjin Medical University Cancer Hospital on the efficacy and safety of carrelizumab combined with apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma The design is selected for the poster link, and we look forward to the announcement of future results.
-
Chinese medicine acyclovir for injection passed the consistency evaluation of generic drugs
Time of Update: 2021-06-11
On June 2, China Pharmaceuticals issued an announcement stating that its subsidiary, Keyi Pharmaceutical, had obtained the "Notice of Approval of Supplementary Application for Drug Application" for acyclovir for injection approved and issued by the State Food and Drug Administration.
The sales revenue of this drug in China Pharmaceuticals in 2020 is approximately RMB 2.
-
Pan Guangcheng resigned as independent director of Kailaiying
Time of Update: 2021-06-11
On June 1, Kailaiying issued an announcement stating that it had recently received a written resignation report from independent director Pan Guangcheng.
Pan Guangcheng applied for the resignation of the company's independent director, strategic committee member, and nomination committee member.
-
Gao Fu: If the vaccine is not shared, the virus will share the world
Time of Update: 2021-06-10
" On the Pujiang Innovation Forum · Global Health and Development Forum held on June 4 in the afternoon, Chinese Academy of Sciences academician , the US National Academy of Sciences foreign academician , director of high Chinese Center for Disease Control and Prevention Fu said so.
-
24 new confirmed cases, 9 of which are local cases are in Guangdong
Time of Update: 2021-06-10
As of 24:00 on June 3, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 371 confirmed cases (including 8 severe cases), a total of 86,187 cured and discharged cases, and a total of 4,636 deaths.
-
China's Kexing Vaccine "entry into the WTO" is essential to contain the global epidemic
Time of Update: 2021-06-10
A report published on the website of the British "Nature" magazine on the 4th said that recently, China's Kexing new crown vaccine was included in the WHO emergency use list, which is "critical to curbing the global new crown pneumonia epidemic.
-
Health Commission: my country's vaccine research and development number ranks first in the world
Time of Update: 2021-06-10
National Health Commission: my country ranks first in the world in terms of the number of vaccine research and development National Health Commission: my country ranks first in the
-
The fifth batch of national drug procurement will open bids, involving anti-cancer drugs, antihypertensive drugs, etc.
Time of Update: 2021-06-10
(China News Network)A few days ago, the National Organization for Pharmaceutical Joint Procurement Office released the fifth batch of national drug procurement product catalogs, and determined 62 varieties to participate in this procurement, including anticancer drugs, antibiotics, hypertension-related drugs, ophthalmology-related drugs, and psychotropic drugs, etc.
-
Who will be the domestic CXO unicorn to share the $244 billion market pie?
Time of Update: 2021-06-10
Figure 4: Statistics on the number of domestic new drug INDs The development trend of China's CXO industry Small molecule drug R&D companies are facing business transformation .
-
Important notice for licensed pharmacist candidates is here
Time of Update: 2021-06-10
According to the news, this year's registered pharmacist vocational qualification examination registration certificate has implemented a notification and commitment system, and applicants can choose whether to use the notification and commitment system.
-
The new patent law is officially implemented! Innovative drug patent protection period can be extended to 14 years
Time of Update: 2021-06-10
In order to compensate for the time spent in the review and approval of new drugs, the patent administration department of the State Council shall, at the request of the patentee, grant compensation for the duration of the patent right for the new drug-related invention patents that have been approved for marketing in China.
-
Qilu broke out!
Time of Update: 2021-06-10
A few days ago, the State Food and Drug Administration's official website showed that Qilu Pharmaceutical's cefazolin sodium for injection has been approved as a supplementary application, and this product is the third domestically-evaluated company.
-
Human Virome Heterogeneity Assessment Report Published
Time of Update: 2021-06-10
" Researcher Ma Zhanshan said, the difference in the virus group The qualitativeness is similar to the heterogeneity of bacteria, but the high variability of viruses also makes it more difficult to classify and identify them.
-
Li Lanjuan's team: The mitochondrial mechanism of necrotizing apoptosis in liver disease
Time of Update: 2021-06-10
A review published by the team of Academician Li Lanjuan from Zhejiang University School of Medicine in IJMS reviewed the various molecular mechanisms of mitochondria-mediated cell necrosis and discussed its role in a variety of liver diseases and potential clinical studies.
-
From monopoly of 3.5 billion to less than 200 million Bayer is besieged by 23 companies including CSPC
Time of Update: 2021-06-10
In the face of the "dilemma" of rivaroxaban that is several times fiercely competitive, will Bayer, which has "experience" with Acarbose, make the same choice this time?On June 3, the day after the fifth batch of centralized procurement documents were released, Eli Lilly announced that it had signed an agreement with Menarini, an Italian pharmaceutical company, to sell Cialis (tadalafil) to the Chinese mainland market.
-
Is the new crown vaccine every year?
Time of Update: 2021-06-10
Focusing on hot topics such as epidemic prevention and control and vaccination of public concern, experts such as Zhang Wenhong, Zheng Zhongwei, Li Lanjuan and others who came to the conference conducted discussions and exchanges and made the latest judgments.